ALD research in worm models: what Alex TLC’s lab visit tells us
Alex TLC shared a visit to an early-stage ALD research project using worm models. Learn what drug repurposing means and what this update can—and cannot—tell families.
Nezglyal for cerebral ALD: understanding the EU authorization
The EU authorized Nezglyal for a defined group of boys with cerebral ALD. Here is who the decision covers, what the study found and what remains uncertain.
ALD Newborn Screening in Denmark: What a Three-Step Study Tested
A Danish screening study explores a laboratory approach, with important limits for interpreting the results.
Why ALD Newborn-Screening Programs Can Differ
A review of published screening programs explains differences in testing and follow-up, and the questions families can ask.
Expanded Cord Blood Transplant for Cerebral ALD: What One Case Can Tell Us
One transplant case offers a research question, not a prediction for another family. Here is what the report can and cannot show.
Visual Changes in Adult Cerebral ALD: What a Three-Person Study Found
A case series describes visual-processing difficulties in three men with adult cerebral ALD. We explain the findings and why they do not predict another person’s experience.
FDA Wants to Hear From Rare-Disease Families: Comments Due December 11
FDA is inviting families to share their perspectives on rare-disease therapy development and review. Here is how to comment by December 11, 2026.
From our family
ALD Stories and Research Conversations
Our family’s story, the questions we’re asking, and what we’re learning about ALD along the way.